MGMT and glioblastoma: To evaluate whether an observed TMT effect is due to the combination of CCNU and temozolomide treatment or due to MGMT promoter methylation per se, which is the most important prognostically relevant marker in glioblastoma, it was important to exclusively include MGMT promoter methylated patients in both cohorts—CeTeG as well as Stupp.